Logo image of 1EXEL.MI

EXELIXIS INC (1EXEL.MI) Stock Fundamental Analysis

Europe - BIT:1EXEL - US30161Q1040 - Common Stock

33.55 EUR
+0.37 (+1.12%)
Last: 10/7/2025, 7:00:00 PM
Fundamental Rating

8

1EXEL gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 79 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making 1EXEL a very profitable company, without any liquidiy or solvency issues. An interesting combination arises when we look at growth and value: 1EXEL is growing strongly while it also seems undervalued. These ratings would make 1EXEL suitable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year 1EXEL was profitable.
In the past year 1EXEL had a positive cash flow from operations.
Each year in the past 5 years 1EXEL has been profitable.
Each year in the past 5 years 1EXEL had a positive operating cash flow.
1EXEL.MI Yearly Net Income VS EBIT VS OCF VS FCF1EXEL.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

1EXEL's Return On Assets of 22.49% is amongst the best of the industry. 1EXEL outperforms 89.87% of its industry peers.
1EXEL has a better Return On Equity (29.62%) than 89.87% of its industry peers.
The Return On Invested Capital of 1EXEL (25.22%) is better than 94.94% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1EXEL is below the industry average of 15.27%.
The 3 year average ROIC (10.78%) for 1EXEL is below the current ROIC(25.22%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 22.49%
ROE 29.62%
ROIC 25.22%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1EXEL.MI Yearly ROA, ROE, ROIC1EXEL.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 150

1.3 Margins

The Profit Margin of 1EXEL (27.01%) is better than 86.08% of its industry peers.
In the last couple of years the Profit Margin of 1EXEL has declined.
1EXEL has a Operating Margin of 33.71%. This is amongst the best in the industry. 1EXEL outperforms 89.87% of its industry peers.
In the last couple of years the Operating Margin of 1EXEL has declined.
1EXEL's Gross Margin of 96.59% is amongst the best of the industry. 1EXEL outperforms 93.67% of its industry peers.
In the last couple of years the Gross Margin of 1EXEL has remained more or less at the same level.
Industry RankSector Rank
OM 33.71%
PM (TTM) 27.01%
GM 96.59%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
1EXEL.MI Yearly Profit, Operating, Gross Margins1EXEL.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1EXEL is creating value.
Compared to 1 year ago, 1EXEL has less shares outstanding
1EXEL has less shares outstanding than it did 5 years ago.
There is no outstanding debt for 1EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
1EXEL.MI Yearly Shares Outstanding1EXEL.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
1EXEL.MI Yearly Total Debt VS Total Assets1EXEL.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

1EXEL has an Altman-Z score of 11.82. This indicates that 1EXEL is financially healthy and has little risk of bankruptcy at the moment.
1EXEL has a better Altman-Z score (11.82) than 87.34% of its industry peers.
1EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.82
ROIC/WACC2.69
WACC9.39%
1EXEL.MI Yearly LT Debt VS Equity VS FCF1EXEL.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B

2.3 Liquidity

1EXEL has a Current Ratio of 3.51. This indicates that 1EXEL is financially healthy and has no problem in meeting its short term obligations.
1EXEL's Current ratio of 3.51 is fine compared to the rest of the industry. 1EXEL outperforms 65.82% of its industry peers.
A Quick Ratio of 3.44 indicates that 1EXEL has no problem at all paying its short term obligations.
1EXEL's Quick ratio of 3.44 is fine compared to the rest of the industry. 1EXEL outperforms 64.56% of its industry peers.
Industry RankSector Rank
Current Ratio 3.51
Quick Ratio 3.44
1EXEL.MI Yearly Current Assets VS Current Liabilites1EXEL.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.74% over the past year.
1EXEL shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.65% yearly.
The Revenue has grown by 10.73% in the past year. This is quite good.
The Revenue has been growing by 17.51% on average over the past years. This is quite good.
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%

3.2 Future

The Earnings Per Share is expected to grow by 22.20% on average over the next years. This is a very strong growth
1EXEL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.31% yearly.
EPS Next Y27.76%
EPS Next 2Y25.29%
EPS Next 3Y26.04%
EPS Next 5Y22.2%
Revenue Next Year7.25%
Revenue Next 2Y9.86%
Revenue Next 3Y11.39%
Revenue Next 5Y10.31%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
1EXEL.MI Yearly Revenue VS Estimates1EXEL.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
1EXEL.MI Yearly EPS VS Estimates1EXEL.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 18.74, the valuation of 1EXEL can be described as rather expensive.
1EXEL's Price/Earnings ratio is rather cheap when compared to the industry. 1EXEL is cheaper than 84.81% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.29. 1EXEL is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 13.46, which indicates a correct valuation of 1EXEL.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1EXEL indicates a rather cheap valuation: 1EXEL is cheaper than 92.41% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.85. 1EXEL is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 18.74
Fwd PE 13.46
1EXEL.MI Price Earnings VS Forward Price Earnings1EXEL.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

1EXEL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1EXEL is cheaper than 86.08% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 1EXEL is valued cheaper than 89.87% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.95
EV/EBITDA 11.65
1EXEL.MI Per share data1EXEL.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1EXEL has an outstanding profitability rating, which may justify a higher PE ratio.
1EXEL's earnings are expected to grow with 26.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.68
PEG (5Y)1.48
EPS Next 2Y25.29%
EPS Next 3Y26.04%

More info and screens

0

5. Dividend

5.1 Amount

1EXEL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXELIXIS INC

BIT:1EXEL (10/7/2025, 7:00:00 PM)

33.55

+0.37 (+1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)10-27 2025-10-27/amc
Inst Owners95.32%
Inst Owner ChangeN/A
Ins Owners2.23%
Ins Owner ChangeN/A
Market Cap9.03B
Analysts77.69
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.5%
Min EPS beat(2)13.99%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)21.76%
Min EPS beat(4)10.66%
Max EPS beat(4)49.01%
EPS beat(8)6
Avg EPS beat(8)17.86%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)12
Avg EPS beat(16)38.79%
Revenue beat(2)1
Avg Revenue beat(2)3.15%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)9.31%
Revenue beat(4)2
Avg Revenue beat(4)3.21%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.17%
Revenue beat(12)5
Avg Revenue beat(12)2.6%
Revenue beat(16)7
Avg Revenue beat(16)2.9%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)2.65%
EPS NQ rev (3m)2.65%
EPS NY rev (1m)3.37%
EPS NY rev (3m)3.37%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)-0.01%
Revenue NY rev (1m)-0.17%
Revenue NY rev (3m)-0.17%
Valuation
Industry RankSector Rank
PE 18.74
Fwd PE 13.46
P/S 4.72
P/FCF 13.95
P/OCF 13.63
P/B 5.17
P/tB 5.34
EV/EBITDA 11.65
EPS(TTM)1.79
EY5.34%
EPS(NY)2.49
Fwd EY7.43%
FCF(TTM)2.4
FCFY7.17%
OCF(TTM)2.46
OCFY7.34%
SpS7.11
BVpS6.48
TBVpS6.28
PEG (NY)0.68
PEG (5Y)1.48
Profitability
Industry RankSector Rank
ROA 22.49%
ROE 29.62%
ROCE 32.1%
ROIC 25.22%
ROICexc 38.09%
ROICexgc 39.72%
OM 33.71%
PM (TTM) 27.01%
GM 96.59%
FCFM 33.81%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexcg growth 3Y9.55%
ROICexcg growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 60.32%
Cap/Sales 0.81%
Interest Coverage 250
Cash Conversion 98.79%
Profit Quality 125.2%
Current Ratio 3.51
Quick Ratio 3.44
Altman-Z 11.82
F-Score8
WACC9.39%
ROIC/WACC2.69
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
EPS Next Y27.76%
EPS Next 2Y25.29%
EPS Next 3Y26.04%
EPS Next 5Y22.2%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%
Revenue Next Year7.25%
Revenue Next 2Y9.86%
Revenue Next 3Y11.39%
Revenue Next 5Y10.31%
EBIT growth 1Y86.61%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year42.25%
EBIT Next 3Y34.74%
EBIT Next 5YN/A
FCF growth 1Y108.65%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y98.36%
OCF growth 3Y20.43%
OCF growth 5Y5.84%